FDA Adverse Event Malfunction Summary report: N

BARDEX® LUBRI-SIL® I.C. ALL-SILICONE FOLEY CATHETER

MDR report key: 7429112 · Received April 13, 2018

Report

Report Number
1018233-2018-01169
Event Type
Malfunction
Date Received
April 13, 2018
Report Date
April 26, 2018
Manufacturer
C.R. BARD, INC. (COVINGTON) -1018233
Product Code
EZL
UDI-DI
00801741025228
PMA / PMN Number
K040504
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
FL, US
Reporter Occupation
PATIENT

Narratives

Additional Manufacturer Narrative · 0

THE DEVICE WAS NOT RETURNED FOR EVALUATION. THE LOT NUMBER IS UNKNOWN; THEREFORE, THE DEVICE HISTORY RECORD COULD NOT BE REVIEWED. THE INSTRUCTIONS FOR USE STATES THE FOLLOWING: "LUBRIL-SIL I.C ANTI-MICROBIAL ALL-SILICONE FOLEY CATHETER WITH BARD HYDROGEL AND BACTI-GUARD SILVER ALLOY COATING INFECTION CONTROL ALL-SILICONE FOLEY CATHETER 100% LATEX-FREE WARNING: ON CATHETER, DO NOT USE OINTMENTS OR LUBRICANTS HAVING PETROLATUM BASE. THEY WILL DAMAGE SILICONE AND MAY CAUSE THE BALLOON TO BURST. WARNING: AFTER USE, THIS PRODUCT MAY BE A POTENTIAL BIOHAZARD. HANDLE AND DISPOSE OF IN ACCORDANCE WITH APPLICABLE LOCAL, STATE, AND FEDERAL LAWS AND REGULATIONS. CAUTION: FEDERAL (U.S.A.) LAW RESTRICTS THIS DEVICE TO SALE BY OR ON THE ORDER OF A PHYSICIAN. CAUTION: DO NOT ASPIRATE URINE THROUGH DRAINAGE FUNNEL WALL. STORAGE: STORE CATHETERS AT ROOM TEMPERATURE AWAY FROM DIRECT EXPOSURE TO LIGHT, PREFERABLY IN THE ORIGINAL BOX. NOTE: AGGRESSIVE TRACTION, PARTICULARLY IN THE PRESENCE OF SUTURING, IS NOT RECOMMENDED FOR 100% SILICONE FOLEY CATHETERS. STERILE UNLESS PACKAGE IS OPENED OR DAMAGED. SINGLE PATIENT USE ONLY. DO NOT REUSE. DO NOT RESTERILIZE. FOR UROLOGICAL USE ONLY. VALVE TYPE: USE LUER SLIP SYRINGE. DO NOT USE NEEDLE. CATHETERS SHOULD BE REPLACED IN ACCORDANCE WITH THE CDC GUIDELINE "GUIDELINE FOR PREVENTION OF CATHETER-ASSOCIATED URINARY TRACT INFECTION". AT THE ONSET OR FIRST SIGNS OF A URINARY TRACT INFECTION, CATHETER ENCRUSTATION, OR ANY OTHER CATHETER-RELATED ADVERSE EFFECT, THE CATHETER SHOULD BE REPLACED. TO DEFLATE CATHETER BALLOON: GENTLY INSERT A SYRINGE IN THE CATHETER VALVE. NEVER USE MORE FORCE THAN IS REQUIRED TO MAKE THE SYRINGE "STICK" IN THE VALVE. IF YOU NOTICE SLOW OR NO DEFLATION, RE-SEAT THE SYRINGE GENTLY. ALLOW THE BALLOON TO DEFLATE SLOWLY ON ITS OWN. DO NOT ASPIRATE OR MANUALLY ACCELERATE THE DEFLATION OF THE BALLOON. IF PERMITTED BY HOSPITAL PROTOCOL, THE VALVE ARM MAY BE SEVERED. IF THIS FAILS, CONTACT ADEQUATELY TRAINED PROFESSIONAL FOR ASSISTANCE, AS DIRECTED BY HOSPITAL PROTOCOL. SHOULD BALLOON RUPTURE OCCUR, CARE SHOULD BE TAKEN TO ASSURE THAT ALL BALLOON FRAGMENTS HAVE BEEN REMOVED FROM THE PATIENT. VISUALLY INSPECT THE PRODUCT FOR ANY IMPERFECTIONS OR SURFACE DETERIORATION PRIOR TO USE. RECOMMENDED INFLATION CAPACITIES 5CC BALLOON: USE 10CC STERILE WATER 30CC BALLOON: USE 35CC STERILE WATER DO NOT EXCEED RECOMMENDED CAPACITIES. BARD AND LUBRI-SIL ARE TRADEMARKS AND/OR REGISTERED TRADEMARKS OF C.R. BARD, INC. *BACTI-GUARD IS A REGISTERED TRADEMARK OF BACTIGUARD AB. ©2011 C. R. BARD, INC. ALL RIGHTS RESERVED."

Description of Event or Problem · 0

IT WAS REPORTED THAT THE BALLOON OF THE CATHETER MUSHROOMED. THE PATIENT EXPERIENCED PAIN DURING REMOVAL OF THE CATHETER.

Additional Manufacturer Narrative · 1

THE INVESTIGATION IS STILL IN PROGRESS. ONCE THE INVESTIGATION IS COMPLETE A SUPPLEMENTAL REPORT WILL BE FILED. THE INFORMATION PROVIDED BY BARD REPRESENTS ALL OF THE KNOWN INFORMATION AT THIS TIME. DESPITE GOOD FAITH EFFORTS TO OBTAIN ADDITIONAL INFORMATION, THE COMPLAINANT / REPORTER WAS UNABLE OR UNWILLING TO PROVIDE ANY FURTHER PATIENT, PRODUCT, OR PROCEDURAL DETAILS TO BARD. THE DEVICE WAS NOT RETURNED.

Description of Event or Problem · 1

IT WAS REPORTED THAT THE BALLOON OF THE CATHETER MUSHROOMED. THE PATIENT EXPERIENCED PAIN DURING REMOVAL OF THE CATHETER.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
274094 BARDEX® LUBRI-SIL® I.C. ALL-SILICONE FOLEY CATHETER LUBRISIL FOLEY CATHETER EZL C.R. BARD, INC. (COVINGTON) -1018233 1758SI16 NA 00801741025228

Patients

Seq Age Sex Outcome Treatment
1